Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ticagrelor vs clopidogrel in Chinese patients with stable CAD
NCT03679091Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Aug 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ticagrelor in coronary artery disease (CAD), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Platelet inhibition ratio at 2 months. Started Aug 2018; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03679091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679091.